Although CHI3L1 appears promising as a serum biomarker in this limited trial and may also provide a mechanistic link to the pathogenesis of liver fibrosis, further testing is needed to validate its use in the routine management of patients with liver fibrosis. The gene discussed is CHI3L1; the disease is Hepatic fibrosis.